235 related articles for article (PubMed ID: 20382507)
1. Correlates, change and 'state or trait' properties of insight in schizophrenia.
Wiffen BD; Rabinowitz J; Lex A; David AS
Schizophr Res; 2010 Sep; 122(1-3):94-103. PubMed ID: 20382507
[TBL] [Abstract][Full Text] [Related]
2. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
[TBL] [Abstract][Full Text] [Related]
3. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
[TBL] [Abstract][Full Text] [Related]
4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
5. Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable.
Rabinowitz J; Napryeyenko O; Burba B; Martinez G; Neznanov NG; Fischel T; Baylé FJ; Cavallaro R; Smeraldi E; Schreiner A
J Clin Psychopharmacol; 2011 Feb; 31(1):75-81. PubMed ID: 21192147
[TBL] [Abstract][Full Text] [Related]
6. Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder.
Wiffen BD; Rabinowitz J; Fleischhacker WW; David AS
Clin Schizophr Relat Psychoses; 2010 Oct; 4(3):169-75. PubMed ID: 20880827
[TBL] [Abstract][Full Text] [Related]
7. Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone.
Gharabawi GM; Lasser RA; Bossie CA; Zhu Y; Amador X
Int Clin Psychopharmacol; 2006 Jul; 21(4):233-40. PubMed ID: 16687995
[TBL] [Abstract][Full Text] [Related]
8. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
[TBL] [Abstract][Full Text] [Related]
9. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
[TBL] [Abstract][Full Text] [Related]
10. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
[TBL] [Abstract][Full Text] [Related]
12. Premorbid functioning and treatment response in recent-onset schizophrenia.
Rabinowitz J; Harvey PD; Eerdekens M; Davidson M
Br J Psychiatry; 2006 Jul; 189():31-5. PubMed ID: 16816303
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
14. Trajectories and antecedents of treatment response over time in early-episode psychosis.
Levine SZ; Rabinowitz J
Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
[TBL] [Abstract][Full Text] [Related]
15. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
16. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.
Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM; Naber D
Schizophr Res; 2010 May; 118(1-3):176-82. PubMed ID: 20080036
[TBL] [Abstract][Full Text] [Related]
17. Patient-based and clinician-based support for the remission criteria in schizophrenia.
Docherty JP; Bossie CA; Lachaux B; Bouhours P; Zhu Y; Lasser R; Gharabawi GM
Int Clin Psychopharmacol; 2007 Jan; 22(1):51-5. PubMed ID: 17159460
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
19. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
20. Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database.
Lambert T; Emmerson B; Hustig H; Resseler S; Jacobs A; Butcher B;
BMC Psychiatry; 2012 Mar; 12():25. PubMed ID: 22448928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
